Mahmood I
Division of Pharmaceutical Evaluation I, Office of Clinical Pharmacology and Biopharmaceutics, Food and Drug Administration, Rockville, MD 20852, USA.
Eur J Drug Metab Pharmacokinet. 1996 Jul-Sep;21(3):275-8. doi: 10.1007/BF03189726.
From this study it is proposed that the clearance of anti-cancer drugs may be best estimated if they follow the following trend: (i) that if the exponent of the allometric equation (clearance vs body weight) lies between 0.55-0.75 (0.75 was chosen after Kleiber's power rule (18)), then a simple allometric equation can predict the clearance reasonably well; (ii) if the exponent of the allometric equation lies between 0.75 to approximately 0.90, clearance can be reasonably predicted using CL x MLP; and (iii) if the exponent of the allometric equation is > or = 0.90, the clearance can be predicted using the product of clearance and brain weight.